Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lifecare AS ( (DE:LFC0) ) has shared an update.
Lifecare ASA has reminded investors that the exercise period for its Series 1 warrants, issued in connection with a rights issue completed in January 2026, runs from 2 March to 13 March 2026, after which any unexercised warrants will lapse worthless and may dilute non-participating holders. The company also disclosed that insider-related Hannibal Invest AS has exercised 615,196 Series 1 warrants at NOK 0.3342 per share, with the resulting share capital increase expected to be registered in late March, underscoring insider support for the financing structure and strengthening Lifecare’s capital base for its sensor technology development.
Following the warrant exercise, Hannibal Invest AS holds 958,158 shares along with remaining Series 1 and Series 2 warrants in Lifecare, increasing its exposure to the company’s future performance. Lifecare expects the new shares to be delivered to subscribers’ VPS accounts around 26 March 2026, marking a key step in finalizing the funding round linked to its ongoing growth plans in the medical sensor and continuous glucose monitoring market.
More about Lifecare AS
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring various body analytes. The company focuses on next-generation continuous glucose monitoring systems based on osmotic pressure sensing, with applications in humans and pets.
YTD Price Performance: -66.20%
Average Trading Volume: 2,767,342
Current Market Cap: NOK73.37M
For an in-depth examination of LFC0 stock, go to TipRanks’ Overview page.